Current vaccines to prevent COVID-19 are highly effective in producing antibodies in pregnant people, resulting in more antibodies than what is generated from a natural SARS-CoV-2 virus infection, according to a study funded by the National Institutes of Health. Moreover, antibodies produced after vaccination are present in breastmilk and travel across the placenta, indicating that vaccination during pregnancy will also confer immunity to newborns.
News
NICHD issues News Releases and Media Advisories to the news media. Spotlight and Research Feature articles explain NICHD research findings and public health issues to the general public. An Item of Interest is a short announcement of relevant information, such as a notable staff change.
Director's Corner: Advancing Research to Understand, Treat, and Prevent Long COVID
For many COVID-19 patients, full recovery remains elusive even long after they should feel “better.” NIH recently announced research opportunities to understand COVID-19 long haulers, who have what researchers now refer to as Post-acute sequelae of SARS-CoV-2 infection (PASC). NICHD joins these opportunities while remaining focused on PASC patients within our audiences of interest—pregnant and lactating people, children, and those with disabilities.
Release: NIH funds study to evaluate remdesivir for COVID-19 in pregnancy
A new study funded by the National Institutes of Health will evaluate the effects of remdesivir in pregnant women who have been prescribed the drug to treat COVID-19. The study, which will be conducted at 17 sites in the continental United States and Puerto Rico, aims to determine how pregnant women metabolize the drug and whether there are any potential side effects.
Media Advisory: NIH calls for greater inclusion of pregnant and lactating people in COVID-19 vaccine research
Pregnant people need to be protected through research rather than from research, the authors contend.
Director's Corner: Including pregnant and lactating people in SARS-CoV-2 vaccine research
As the COVID-19 pandemic persists, SARS-CoV-2 vaccines offer the potential to halt the spread of the virus. Yet, we know very little about the effectiveness and safety of the vaccines during pregnancy.
Media Advisory: Severe COVID-19 in pregnancy associated with preterm birth, other complications
NIH-funded study suggests mother-to-infant transmission appears to be rare
Science Update: Childbirth during COVID-19 pandemic associated with anxiety, post-traumatic stress symptoms, NIH-supported study suggests
Increased stress may interfere with adjustment to new motherhood, mother-infant bonding
Director's Corner: Reflecting on our Science Advances in 2020
2020 was a year filled with many challenges. NICHD remained focused on our core mission, advancing key research in women’s health, reproductive science, rare childhood diseases and many more. Watch the video below and review our research highlights of 2020.
Spotlight: Selected NICHD Research Advances of 2020
Read about NICHD’s research findings and activities from 2020.
Science Update: COVID-19 in third trimester may reduce level of SARS-CoV-2 antibodies transferred across the placenta
For pregnant women with COVID-19 in the third trimester, antibodies against the SARS-CoV-2 virus appear to be transferred to the fetus at lower levels, compared to antibodies against two other respiratory diseases, suggests a study funded by the National Institutes of Health. However, one type of antibody against SARS-CoV-2 was transferred to the fetus more efficiently than the other antibodies against the virus, raising the possibility of at least some immune protection against the disease for the newborn.
Release: Pregnant women in third trimester unlikely to pass SARS-CoV-2 infection to newborns
Pregnant women who are infected with SARS-CoV-2, the virus that causes COVID-19, during the third trimester are unlikely to pass the infection to their newborns, suggests an NIH-funded study.
Media Advisory: NIH-supported study to track prevalence and impact of SARS-CoV-2 among pregnant women in low- and middle-income countries
The study of approximately 16,000 pregnant women will continue 12 months after childbirth and compare maternal, fetal and newborn outcomes of participants infected with the virus to those of pregnant women who have not.
Media Advisory: Placenta lacks major molecules used by SARS-CoV-2 virus to cause infection
The placental membranes that contain the fetus and amniotic fluid lack the messenger RNA (mRNA) molecule required to manufacture the ACE2 receptor, the main cell surface receptor used by the SARS-CoV-2 virus to cause infection, according to a study by researchers at the National Institutes of Health.
Director's Corner: COVID-19 Testing Technologies
As the nation begins to return to work and businesses re-open, reliable COVID-19 testing is needed. NIH is rising to the challenge.
Director's Corner: Responding to COVID-19
Crisis often brings out the best in us. Recognizing one of NICHD’s essential workers on the front lines of the response to COVID-19 in New Mexico’s Navajo Nation.
Media Advisory: NIH-funded study to investigate pregnancy outcomes resulting from the COVID-19 pandemic
Researchers to evaluate medical records of 21,000 pregnant women